CMX-2043 is under clinical development by Ischemix and currently in Phase I for Traumatic Brain Injury. According to GlobalData, Phase I drugs for Traumatic Brain Injury does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CMX-2043 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CMX-2043 overview
CMX-2043 is under development for the prevention of peri-operative cardiac ischemia-reperfusion injury in patients undergoing elective percutaneous coronary intervention (PCI) procedures, prevention of delayed graft function in connection with kidney transplants, and treatment of traumatic brain injury. The drug candidate is a small molecule. It is administered by both intravenous and intravenous bolus injection. CMX-2043 is a cardio-protective drug that combines Akt pathway-mediated cell survival effects and anti-oxidant activity. It was also under development for the prevention of cardiac and renal injury associated with coronary angiography in patients with the acute coronary syndrome.
Ischemix overview
Ischemix, formerly CereMedix, is a clinical stage pharmaceutical company that develops novel compounds for cytoprotective in the kidney, heart and other organ systems. The company’s major product includes CMX-2043, a modified natural compound that activates cell survival pathways and blocks oxidative damage. Its product is used for prevention of contrast-induced acute kidney injury following coronary interventions. Ischemix also develops novel cytoprotective compounds based on a natural co-factor and alpha lipoic acid, which is linked to sequences of natural amino acids. The company offers prevention of hospital-acquired kidney injury (HA-AKI) and cardiac injury associated with PCI. Ischemix is headquartered in North Grafton, Massachusetts, the US
For a complete picture of CMX-2043’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
